Epstein-barr Virus

• & USAGE SECTION Law of similars - Use according to standard homeopathic indications.

DOSAGE & ADMINISTRATION SECTION Directions: Ages 12 and up, take 6 drops by mouth, (Ages 0 to 11, give 3 drops) as needed or as directed by a health professional.

SECTION Warning: Keep out of reach of children. Do not use if tamper - evident seal is broken or missing. If symptoms worsen or persist for more than a few days, consult a doctor. If pregnant or breast-feeding, ask a doctor before use.

1. 1Aids Encephalopathy125%
2. 2Finger Deformity125%
3. 3Fungal Infection125%
4. 4Haemoglobin Decreased125%
5. 5Lymphocyte Count Increased125%
6. 6Muscle Spasms125%
7. 7Opportunistic Infection125%
8. 8Platelet Count Decreased125%
9. 9Prostatitis125%
10. 10Pulmonary Embolism125%
11. 11Skin Disorder125%

Recent PubMed references pinned to Epstein-barr Virus as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Epstein-Barr virus-associated multiple sclerosis: recent mechanistic advances and clinical therapeutic perspectives.
  Frontiers in immunology · 2026 · Cheng R, Gao Y, Zheng R, et al.
  PMID 42253989DOI 10.3389/fimmu.2026.1799161
• Progress toward an Epstein-Barr virus vaccine.
  Expert review of vaccines · 2026 · Laferriere C, Bland E, Channon W, et al.
  PMID 42253055DOI 10.1080/14760584.2026.2686294
• Synergistic Oncogenesis Cooperative Role of Epstein Barr Virus and Human Papillomavirus in Cancer Progression.
  Reviews in medical virology · 2026 · Jindal N, Rana S, Mishra BB, et al.
  PMID 42250259DOI 10.1002/rmv.70173
• Rogue clones: When MS autoimmunity goes viral.
  Science immunology · 2026 · Lünemann JD
  PMID 42247484DOI 10.1126/sciimmunol.aej1959
• Epidemiological Trends and Clinical Characteristics of Epstein-Barr Virus Infection in Febrile Children in Zhejiang, China: A Retrospective Study.
  Immunity, inflammation and disease · 2026 · Zhou H, Ru X, Jin W, et al.
  PMID 42237472DOI 10.1002/iid3.70468
• [Immune deficiency/dysregulation-associated lymphoma with an immunophenotype resembling EBV-positive nodal T/NK-cell lymphoma during treatment of follicular lymphoma].
  [Rinsho ketsueki] The Japanese journal of clinical hematology · 2026 · Maeda Y, Harada T, Hori T, et al.
  PMID 42236239DOI 10.11406/rinketsu.67.379
• Reconstructing EBV reactivation and DNA damage response kinetics in morphologic pseudotime.
  Proceedings of the National Academy of Sciences of the United States of America · 2026 · Tekle DG, Dobry CJ, Sexton JZ, et al.
  PMID 42234528DOI 10.1073/pnas.2609598123
• Epstein-Barr Virus Entry: An Updated Review.
  Journal of medical virology · 2026 · Zhang T, Li ZQ, Pang D, et al.
  PMID 42233529DOI 10.1002/jmv.70996

The 10 most recently updated of 258 ClinicalTrials.gov registrations naming Epstein-barr Virus as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
  Active not recruiting · Phase 1 · Interventional · 19 enrolled · Memorial Sloan Kettering Cancer Center
  NCT01430390updated 2026-06-12
• TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
  Recruiting · Phase 1 · Interventional · 47 enrolled · Baylor College of Medicine
  NCT04013802updated 2026-06-11
• A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years
  Active not recruiting · Observational · 100 enrolled · Sanofi Pasteur, a Sanofi Company
  NCT07536048updated 2026-06-11
• Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
  Recruiting · Phase 2 · Interventional · 156 enrolled · National Cancer Institute (NCI)
  NCT06029270updated 2026-06-11
• Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
  Recruiting · Phase 1 · Interventional · 18 enrolled · Baylor College of Medicine
  NCT04288726updated 2026-06-10
• LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers
  Recruiting · Observational · 105 enrolled · University Health Network, Toronto
  NCT04665388updated 2026-06-09
• Application of Endoscopic Selective Neck Dissection Under Multimodal Assessment for Residual Cervical Lymph Nodes in N3 Nasopharyngeal Carcinoma After Radiotherapy
  Active not recruiting · Phase 1 · Interventional · 50 enrolled · Guiquan Zhu
  NCT07636499updated 2026-06-09
• Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
  Recruiting · Phase 2 · Interventional · 40 enrolled · National Cancer Institute (NCI)
  NCT03258567updated 2026-06-05
• Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
  Recruiting · Phase 1 · Interventional · 25 enrolled · National Cancer Institute (NCI)
  NCT05389423updated 2026-06-01
• Genetic Studies of Chronic Active Epstein-Barr Disease
  Recruiting · Observational · 300 enrolled · National Institute of Allergy and Infectious Diseases (NIAID)
  NCT00032513updated 2026-06-01

Frequently asked questions

What is Epstein-barr Virus used for?

According to FDA labeling, Epstein-barr Virus carries indications including: & USAGE SECTION Law of similars - Use according to standard homeopathic indications.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.